Premium
Digoxin Pharmacokinetics and Perindopril in Heart Failure Patients
Author(s) -
Vandenburg M. J.,
Stephens J. D.,
Resplandy G.,
Dews I. M.,
Robinson J.,
Desche P.
Publication year - 1993
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1993.tb03935.x
Subject(s) - digoxin , perindopril , medicine , heart failure , pharmacokinetics , digitalis , diuretic , pharmacology , concomitant , cardiology , blood pressure
The influence of chronic perindopril treatment on digoxin pharmacokinetics was investigated in 10 patients with mild chronic heart failure under stable diuretic and digitalis treatment and normal renal function. Digoxin was administered at a dose of 0.125 mg/day (n = 2) or 0.250 mg/day (n = 8). The 24‐hour steady‐state digoxin profile was assessed before and after concomitant administration of perindopril for 1 month at doses of 2 mg once a day for the first 8 days and 4 mg once a day for the remaining 21 days. Chronic treatment with perindopril produced no significant effect on mean (± standard deviation) digoxin serum area under the curve for 24 hours (17.9 ± 7.4 versus 16.3 ± 4.4 ng/mL · h), peak digoxin concentration (1.3 ± 0.54 versus 1.2 ± 0.36 ng/mL), time to peak concentration (3 versus 4 hours), and apparent oral clearance of digoxin (237.7 ± 109.6 versus 237.4 ± 79.5 mL/min). Clinical and biologic tolerance of perindopril was good throughout the study. Chronic administration of perindopril did not alter steady‐state digoxin kinetics in patients with mild chronic heart failure and normal renal function, indicating that no adaptation of the digoxin dose is required during co‐prescription with perindopril in such patients.